ArriVent BioPharma, Inc. AVBP Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s cash & equivalents?
- ArriVent BioPharma, Inc. (AVBP) reported cash & equivalents of $62.1M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s cash & equivalents changed year-over-year?
- ArriVent BioPharma, Inc.'s cash & equivalents increased by 24.5% year-over-year, from $49.87M to $62.1M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s cash & equivalents has grown at a -45.0% compound annual growth rate (CAGR), from $150.39M to $45.54M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.